Compare · ARGX vs TECX
ARGX vs TECX
Side-by-side comparison of argenx SE (ARGX) and Tectonic Therapeutic Inc. (TECX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and TECX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.34B, about 81.2x TECX ($656.8M).
- Over the past year, ARGX is up 52.9% and TECX is up 50.2% - ARGX leads by 2.7 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- ARGX has more recent analyst coverage (25 ratings vs 11 for TECX).
- Company
- argenx SE
- Tectonic Therapeutic Inc.
- Price
- $858.23-2.08%
- $34.76+1.18%
- Market cap
- $53.34B
- $656.8M
- 1M return
- -4.38%
- +18.05%
- 1Y return
- +52.92%
- +50.25%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 2
- 2
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
Latest TECX
- Chief Scientific Officer Mcnamara Peter exercised 172 shares at a strike of $14.71 and sold $6,020 worth of shares (172 units at $35.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Reicin Alise covered exercise/tax liability with 924 shares, decreasing direct ownership by 0.30% to 310,623 units (SEC Form 4) to cover taxes
- SEC Form 4 filed by Chief Financial Officer Lochner Daniel
- Tectonic Therapeutic Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Director Tipirneni Praveen P.
- SEC Form 4 filed by Director Donenberg Phillip B.
- SEC Form 4 filed by Director Springer Timothy A
- SEC Form 4 filed by Director Vitorovic Stefan
- SEC Form 4 filed by Director Chutter Jessica Caroline
- SEC Form 3 filed by new insider Chutter Jessica Caroline